Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr 1;199(7):991-8.
doi: 10.1086/597124.

Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care

Diana C Lemly  1 , Bryan E Shepherd, Todd Hulgan, Peter Rebeiro, Samuel Stinnette, Robert B Blackwell, Sally Bebawy, Asghar Kheshti, Timothy R Sterling, Stephen P Raffanti
Affiliations

Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care

Diana C Lemly et al. J Infect Dis. .

Abstract

Background: There are conflicting data regarding race, sex, and mortality among persons infected with human immunodeficiency virus (HIV). We studied all-cause mortality among persons in care during the highly-active antiretroviral therapy (HAART) era.

Methods: This retrospective cohort study included patients who made>or=1 clinic visit from January 1998 through December 2005.

Results: Of 2605 patients (with 6657 person-years of follow-up), 38% were black and 24% were female. The percentage of time in care while receiving HAART was lower for blacks than for nonblacks (47% vs. 76%; P<.001) and for females than for males (57% vs. 71%; P=.01). There were 253 deaths (38 per 1000 person-years). After adjustment for characteristics at baseline, death was associated with black race (hazard ratio [HR], 1.33; P .04), female sex (HR, 1.53; P .007), injection drug use (IDU) as a risk factor for HIV infection (HR, 1.61; P .009), older age (HR, 1.45 per 10 years; P<.001), a lower CD4 cell count (HR, 0.59 for 200 vs. 350 cells/mm3; P<.001) and a higher HIV type 1 RNA level (HR, 1.35; P<.001). After adjustment for the length of time that HAART was received, black race (HR, 1.00; P .99) and IDU (HR, 1.37; P .09) were no longer associated with death, but female sex was (HR, 1.62; P=.002).

Conclusions: Race-associated differences in mortality likely resulted from HAART use. Women had an increased risk of death even after adjustment for HAART use. Addressing racial disparities will require improved HAART utilization. Increased mortality among women requires further study.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest: none reported.

Figures

Figure 1.
Figure 1.
Kaplan-Meier survival curve of the time to death in the total cohort, by race.
Figure 2.
Figure 2.
Kaplan-Meier survival curve of time to death in the total cohort, by sex.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Palella F Jr, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853–60. - PubMed
    1. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22–9. - PubMed
    1. Levine RS, Briggs NC, Kilbourne BS, et al. Black-white mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996. Am J Public Health 2007; 97:1884–92. - PMC - PubMed
    1. Hariri S, McKenna MT. Epidemiology of human immunodeficiency virus in the United States. Clin Microbiol Rev 2007; 20:478–88. - PMC - PubMed
    1. Centers for Disease Control and Prevention. Cases of HIV infection and AIDS in the United States and dependent areas, 2005 HIV/AIDS Surveillance Report. Vol 17 Revised ed. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, June 2007.

Publication types

Substances